Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species

Numinus files a patent application for a “process” that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.

Read more
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine’s novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.

Read more
Microdosing LSD modulates the perception of time independently of other consciousness-altering effects

Lysergic acid diethylamide, or LSD, is a drug which produces a variety of cognitive, perceptual and behavioral changes in users.

Read more
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board

The newest member of Cybin’s Clinical Advisory Board previously held a senior position with the FDA.

Read more
House Committee Approves Marijuana Protections For Banking And D.C.

A House subcommittee on Thursday approved a large-scale funding bill that includes provisions protecting banks from being punished for working with marijuana businesses and allowing Washington, D.C. to legalize cannabis sales.

Read more
Psychedelic Medicine: Will The High Always Be Part Of The Therapy?

Psychedelic Stock Watch explains why astute investors will put their dollars into both “experiential” and non-psychoactive psychedelic drug R&D.

Read more
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.

Read more
Alternatives to ATAI: Go Big Or Go Small?

Sometimes biggest is not “best”. Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.

Read more
Roth Initiates Coverage On Mydecine Innovations With A 9x Price Target

Investors of Mydecine Innovations Group received a pleasant surprise Tuesday morning, drawing coverage from a firm that is making itself known in the psychedelics industry.

Read more
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer

Novamind’s new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )